Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

Not yet recruiting

1

Start Date 12/31/2025

Age of Trial (yrs) .2

KIT + VGKC inhibitor

Inhibit cell proliferation and migration/invasion, as well as induce apoptosis

Specifically GIST and only GIST

811484

University of California, San Diego

Paul Fanta, MD Jason Sicklick, MD (858) 822-5354 cancerCTO@health.ucsd.edu

Oral

Partial Inclusion Criteria (See NCT listing for full criteria)

Having been pathologically confirmed to have a KIT exon 11 mutant gastrointestinal stromal tumor assessed for KIT variant mutations by next generation sequencing
Treatment naïve gastrointestinal stromal tumor
Described as a primary localized or locally advance gastrointestinal stromal tumor in any location that would benefit from neoadjuvant therapy before tumor surgical resection
Has measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors v1.1.

Partial Exclusion Criteria (See NCT listing for full criteria)

KIT exon 9, 13, 14, 17, or 18 mutant gastrointestinal stromal tumor by next generation sequencing.
Non-KIT mutant gastrointestinal stromal tumor
Newly diagnosed with metastatic gastrointestinal stromal tumor
Have residual tumor following surgical debulking